Your browser is no longer supported. Please, upgrade your browser.
Settings
CYAD Celyad SA daily Stock Chart
CYAD [NASD]
Celyad SA
Index- P/E- EPS (ttm)-7.20 Insider Own0.11% Shs Outstand9.53M Perf Week9.96%
Market Cap281.77M Forward P/E- EPS next Y- Insider Trans- Shs Float6.81M Perf Month-1.37%
Income- PEG- EPS next Q- Inst Own5.15% Short Float1.87% Perf Quarter-28.31%
Sales4.35M P/S64.73 EPS this Y- Inst Trans- Short Ratio12.87 Perf Half Y-34.70%
Book/sh5.92 P/B4.99 EPS next Y- ROA- Target Price74.50 Perf Year-15.49%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range25.55 - 64.75 Perf YTD-31.37%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-54.32% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low15.77% ATR1.43
Employees70 Current Ratio- Sales Q/Q-93.40% Oper. Margin- RSI (14)42.85 Volatility2.51% 2.95%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.92 Prev Close28.88
ShortableNo LT Debt/Eq- Earnings- Payout- Avg Volume9.91K Price29.58
Recom2.00 SMA20-7.27% SMA50-10.33% SMA200-31.88% Volume19,049 Change2.42%
May-25-18Initiated Wells Fargo Outperform $44
May-23-18 01:00AM  Celyad Announces Closing of Global Offering GlobeNewswire
May-18-18 08:00AM  Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved Benzinga
May-17-18 09:02AM  Celyad announces pricing of $47.3 million global offering GlobeNewswire -7.79%
May-16-18 08:10AM  Benzinga's Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings Benzinga -8.04%
May-15-18 04:47PM  Celyad Announces First Quarter 2018 Business Update GlobeNewswire -7.49%
04:46PM  Celyad announces launch of proposed global offering GlobeNewswire
May-09-18 01:00AM  Celyad Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2018 GlobeNewswire
May-03-18 01:00AM  Celyad Successfully Administers CYAD-01 in First Patients in SHRINK and LINK Trials GlobeNewswire
Apr-27-18 10:42AM  What Should Investors Know About Celyad SAs (NASDAQ:CYAD) Growth? Simply Wall St. +15.71%
02:30AM  Haematologica publishes Celyad THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed/Refractory AML Patient GlobeNewswire
Apr-26-18 08:56AM  Celyad SA (EBR:CYAD): Whats The Analyst Consensus Outlook? Simply Wall St.
Mar-29-18 01:00AM  Celyad to Present Updates on CYAD-01 at the American Association for Cancer Research (AACR) Annual Meeting 2018 GlobeNewswire
Mar-22-18 04:01PM  Celyad Reports 2017 Financial and Operating Results and Expected Key Milestones for 2018 GlobeNewswire
Oct-30-17 09:40AM  Edison Issues ADR Update on Celyad (CYAD) ACCESSWIRE
Sep-05-17 02:59PM  Celyad SA :CYAD-US: Earnings Analysis: For the six months ended June 30, 2017 : September 5, 2017 Capital Cube
Aug-14-17 08:00AM  Edison Issues Update on Celyad (CYAD) ACCESSWIRE +5.74%
Jul-31-17 06:30AM  BioLife Solutions Executes Supply Agreement with Celyad for CryoStor® Use in Natural Killer Receptor based T-Cell (NKR-T) Platform Targeting Solid Tumors and Blood Cancers PR Newswire
Jun-19-17 08:53AM  3 Biotech Stocks That More than Doubled Year to Date Zacks
Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead oncology candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a single dose escalation Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.